Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Namenda (memantine)
- valganciclovir
Interactions between your drugs
valGANciclovir memantine
Applies to: valganciclovir, Namenda (memantine)
Theoretically, the concomitant administration of memantine and other drugs that undergo active renal tubular secretion may result in altered plasma levels of both drugs. The clinical significance is unknown. When hydrochlorothiazide/triamterene and memantine were coadministered in a clinical study, the bioavailability of hydrochlorothiazide decreased by 20% and there was no change in memantine or triamterene bioavailability.
References (1)
- (2003) "Product Information. Namenda (memantine)." Forest Pharmaceuticals
Drug and food interactions
valGANciclovir food
Applies to: valganciclovir
ADJUST DOSING INTERVAL: Food increases the bioavailability of ganciclovir from the prodrug, valganciclovir. In 16 HIV-positive subjects, the administration of valganciclovir 875 mg once daily with a high-fat meal containing approximately 600 calories resulted in a 30% increase in the steady-state area under the plasma concentration-time curve (AUC) and a 14% increase in the peak plasma concentration (Cmax) of ganciclovir, with no delay in the time to reach peak plasma concentration (Tmax). The mechanism is unknown.
MANAGEMENT: The manufacturer recommends that valganciclovir be taken with meals.
References (2)
- (2001) "Product Information. Valcyte (valganciclovir)." Roche Laboratories
- Brown F, Banken L, Saywell K, Arum I (1999) "Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositiv volunteers." Clin Pharmacokinet, 37, p. 167-76
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Aricept
Aricept is used to treat mild to severe dementia caused by Alzheimer's disease. Learn about side ...
Exelon
Exelon (rivastigmine) is used to treat dementia caused by Alzheimer's or Parkinson's disease ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Leqembi
Leqembi (lecanemab) is used to treat Alzheimer’s disease to help slow the progression of dementia s ...
Namzaric
Namzaric (memantine/donepezil) is used to treat Alzheimer's Disease. Includes Namzaric side ...
Kisunla
Kisunla (donanemab) is used to treat Alzheimer’s disease to help slow down the decline in memory, t ...
Razadyne
Razadyne information from Drugs.com, includes Razadyne side effects, interactions and indications.
Zunveyl
Zunveyl (benzgalantamine) is used to treat mild to moderate dementia in Alzheimer's disease (AD) ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.